Table 6 Adverse events reported in the included studies
From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review
Study ID | Sample size | Intervention | At least 1 adverse event n(%) | Adverse event during follow up, n(%) | Event allegedly caused drug n(%) | Serious adverse event n(%) |
|---|---|---|---|---|---|---|
1 | 27 | Omalizumab 75-375 mg | 22 (81.5) | - | 6 (22.2) | - |
22 | Placebo | 19 (86.4) | - | 6 (22.7) | - | |
2 | 23 | Omalizumab 75 mg | 8 (34.8) | 9 (50.0) | - | - |
25 | Omalizumab 300 mg | 12 (48.0) | 12 (52.2) | - | - | |
21 | Omalizumab 600 mg | 10 (47.6) | 5 (25.0) | - | - | |
21 | Placebo | 10 (47.6) | 7 (35.0) | - | - | |
3 | 82 | 75 mg omalizumab | 45 (59) | - | 7 (9) | 4 (5) |
83 | 150 mg omalizumab | 59 (67) | - | 8 (9) | 5 (6) | |
79 | 300 mg omalizumab | 51 (65) | - | 7 (9) | 6 (8) | |
79 | placebo | 48 (61) | - | 3 (4) | 7 (9) | |
4 | 252 | Omalizumab 300 mg | 211 (83.7) | - | 28 (11.1) | 18 (7.1) |
84 | Placebo | 65 (78.3) | - | 11 (13.3) | 5 (6) | |
5 | 78 | Omalizumab 75 mg | 55 (78.6) | 36 (51.4) | 6 (8.6) | 2 (2.9) |
80 | Omalizumab 150 mg | 72 (82.8) | 45 (51.7) | 9 (10.3) | 5 (5.7) | |
81 | Omalizumab 300 mg | 57 (70.4) | 38 (46.9) | 14 (17.3) | 2 (2.5) | |
80 | Placebo | 53 (66.3) | 32 (40.0) | 4 (5.0) | 5 (6.3) |